Kolexia
Garciaz Sylvain Hématologie
Garciaz Sylvain
Hématologie
Centre Paoli-Calmettes
Marseille, France
141 Activités
251 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Lymphomes Maladie de Hodgkin Lymphome malin non hodgkinien Lymphome B Leucémie-lymphome lymphoblastique à précurseurs B et T Lymphome B diffus à grandes cellules

Collaborateurs

Voir plus
Vey Norbert
Vey Norbert
Centre Paoli-Calmettes, Marseille, France
Bouabdallah Reda
Bouabdallah Reda
Cabinet libéral, Aix-en-Provence, France
Blaise Didier
Blaise Didier
Centre Paoli-Calmettes, Marseille, France
Hospital Marie-Anne
Hospital Marie-Anne
Centre Paoli-Calmettes, Marseille, France

Industries

Voir plus
Abbvie
5 collaboration(s)
Dernière en 2023
Amgen
4 collaboration(s)
Dernière en 2022
Novartis
4 collaboration(s)
Dernière en 2023
Janssen
4 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Caspase-2 protects against ferroptotic cell death.
Cell death & disease   01 mars 2024
VENAZA: Results From a Nationwide Cohort Temporary Utilization Authorization (ATU) of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC),Treated in France With Venetoclax Azacitidine
Essai Clinique (French Innovative Leukemia Organisation)   15 février 2024
Long-term survival of AML treated with intensive chemotherapy with extensive molecular data available.
Leukemia & lymphoma   08 février 2024
A Single Center Real World Experience of Allogeneic HSCT of Patients with MDS/CMML in Aged Population
Abstracts from the 2024 Tandem Meetings of ASTCT and CIBMTR, February 21-24, 2024, San Antonio, Texas, USA   01 février 2024
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Phase 1, Open-label, Dose Finding Study of CC-95251 Alone and in Combination With Antineoplastic Agents in Subjects With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Essai Clinique (BMS)   02 janvier 2024
Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.
European journal of haematology   29 novembre 2023
Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Bone marrow transplantation   03 novembre 2023
Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
65th ASH Annual Meeting Abstracts   02 novembre 2023
A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations
65th ASH Annual Meeting Abstracts   02 novembre 2023
Preliminary Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias
65th ASH Annual Meeting Abstracts   02 novembre 2023